US biotechnology company Dyadic Applied BioSolutions has appointed Intralink to support its expansion across Europe.

Florida-based Dyadic develops precision-engineered, animal-free proteins and enzymes for the life sciences, food and nutrition and industrial sectors. The company has already established relationships with a range of prospective partners and customers in Europe and sees substantial potential for its technologies in the region as it seeks to expand the commercial adoption of its recombinant protein technologies and establish new partnerships across life sciences markets.

Intralink is a business development consultancy which specialises in helping companies secure customers, partners and investors in overseas markets. It has a presence in 27 locations including Silicon Valley, Boston, London, Paris, Düsseldorf, Poznań, Tokyo, Shanghai, Taipei, Bangkok and New Delhi.

Intralink’s appointment to support Dyadic in Europe builds on the business development programmes it is already running on the company’s behalf in Japan and South Korea, which have created new strategic relationships and generated a range of significant commercial opportunities.

Initially, Dyadic aims to introduce two flagship products to the European market: DNase I (RNase-free), an enzyme used in biologics and mRNA manufacturing, and Human Transferrin, a recombinant form of transferrin widely used in research and cell culture media for biopharmaceutical production.

Intralink’s Europe-based team will deliver a targeted campaign to identify, prioritise and engage potential partners, distributors and customers. It will focus primarily on European reagent distributors, together with companies operating in the pharmaceutical and biotechnology sectors. The team’s goal is to strengthen Dyadic’s existing relationships, while securing additional direct supply partners, platform licensing opportunities and strategic collaborations.

Joe Hazelton, President & Chief Operating Officer of Dyadic Applied BioSolutions, said: “European pharma, biotech and life science companies are increasingly focused on improving manufacturing efficiency, securing reliable supply chains and transitioning towards high-performance animal-free components. Our recombinant protein platforms and wider product portfolio are designed to address these needs by enabling the scalable, cost-effective production of complex proteins and enzymes.

“We see significant opportunities in Europe for our commercial recombinant products, including DNase I and Human Transferrin, as well as for broader strategic collaborations involving strain licensing, platform access and custom protein development programmes.”

He added: “Following the strong engagement and increasing commercial interest in our products generated by Intralink in Japan and South Korea, we believe the company’s deep sector expertise and established European networks make it the ideal partner to now help us expand our footprint across this region, too.
“We look forward to building new relationships with European distributors, manufacturers and biotech innovators seeking next-generation recombinant production solutions.”

Dr Corey Monteith, a specialist in Intralink’s Medtech & Life Sciences Practice, explained: “Biotech and pharma companies across Europe are seeking partnerships and investment opportunities with innovative global businesses like Dyadic that offer the potential to produce high-quality products efficiently and at scale.

“We’re looking forward to helping Dyadic to build on the significant interest it has already established across Europe and to grow its presence in this essential biotech market.”

For more media information, interviews or images, please contact:
Rebecca George: rebecca.george@tk-associates.com | +44 7974 161 108